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Search strategy and selection criteria 
References for this review were conducted using PubMed and EMBASE. Relevant articles, 
websites, and book sections were considered. Non-English articles have been included in some 
cases. Search terms included “Clonorchis sinensis”, “clonorchiasis”, “Opisthorchis viverrini”, 
“Opisthorchis felineus”, “Opisthorchiasis”, “Liver fluke”, “Food-borne trematodes”, “Food-borne 
trematodiasis”, “Cholangiocarcinoma”. The final reference list was generated on the basis of 
relevance to the broad scope of the review. 
 
SUMMARY 
Human liver fluke infections are encountered worldwide. In some areas of 
the developing world a combination of ecological, agricultural and culinary 
factors leads to a very high prevalence of infection, but in the developed 
world they are uncommon. Infection is associated with considerable 
morbidity and several are recognised as biological carcinogens. In this 
article, we review the epidemiology, clinical significance, and diagnostic 
and treatment strategies of human infection with these pathogens. 
 
 
INTRODUCTION 
Flukes are large, multicellular, leaf-like organisms of the phylum 
Platyhelminthes, class trematoda. More than 6000 species have been described 
and at least 100 of these are capable of infecting humans. In order to use 
vertebrates as a definitive host, the adult fluke must migrate to a tissue that 
provides a portal of exit for its ova. The common names given to these pathogens 
reflect tissue tropism of the adult fluke in humans. Adult members of the genera 
Fasciola, Clonorchis and Opisthorchis (the common liver flukes) reside in the 
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biliary tract. Paragonimus spp. (lung flukes) migrate to pulmonary tissue, 
Echinostoma and Fasciolopsis (intestinal flukes) remain in the small bowel and 
species of Schistosoma are sometimes referred to as blood flukes as the adult 
worm resides in blood vessels. 
 
Together the liver, lung, and intestinal flukes are referred to as the food-borne 
trematodiases. Collectively, these have been designated as one of 17 Neglected 
Tropical Diseases (NTDs). In 2012, the World Health Organization (WHO) 
released a roadmap detailing strategy and specifying targets for the control of 
NTDs(1). Food-borne trematodiases remain amongst the most neglected of 
NTDs(2). Estimates of prevalence are hard to calculate as most trematodiases are 
geographically and ecologically circumscribed, with areas of hyperinfestation 
interspersed with areas which are free of infection. Within endemic 
communities, parasites are also highly aggregated, with a few individuals 
harbouring the majority of parasites(3). Overall, the WHO estimates that 56 
million individuals are infected with one of the four main genera of food-borne 
trematodes, a figure that is very likely to be an underestimate (4). 
 
Flukes known to parasitise the human liver include the Opisthorchidae 
(Clonorchis sinensis [the Chinese liver fluke], Opisthorchis felineus, Opisthorchis 
viverrini, Metorchis conjunctus [the North American liver fluke], Metorchis bilis, 
Amphimerua noverca, Opisthorchis guayaquilensis, Pseudamphistomum 
truncatum, and possibly Metorchis orientalis); the Fasciolidae (Fasciola hepatica 
and Fasciola gigantica) and the Dicrocoeliidae (Dicrocoelium dendriticum [the 
Lanceolate liver fluke] , Dicrocoelium hospes, and Eurytretna pancreaticum)(5). 
The most important of these are C. sinensis, causing human clonorchiasis, O. 
viverrini and O. felineus (the Far Eastern Liver Flukes), causing human 
opisthorchiasis and F. hepatica and F. gigantica, which cause human fascioliasis. 
These will be addressed in most detail in this review.  
 
Disease associated with liver fluke infection tends to be insidious although acute 
disease associated with parasite migration through tissue can occur. Chronic 
infection with Clonorchis sinensis or Opisthorchis viverrini is strongly associated 
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with the development of cholangiocarcinoma and both have been recognised as 
class 1 biological carcinogens(6). 
 
PARASITE LIFE CYCLES 
The life cycles of Clonorchis and Opisthorchis can be considered together. Eggs 
are excreted in the faeces of infected definitive hosts, with each egg containing a 
single miracidium. When an egg is ingested by a suitable intermediate 
freshwater snail host, a miracidium is hatched and develops into a sporocyst 
then rediae. Within the snail, asexual reproduction occurs, resulting in the 
production of thousands of cercariae which are periodically released into the 
environment. Free swimming cercariae penetrate and embed themselves in the 
flesh of cyprinoid freshwater fish (second intermediate host) and encyst as 
metacercariae. Fish eating mammals (ie: cats, dogs, pigs) are common definite 
hosts. Humans are often incidental hosts, but can be definite hosts in O. viverrini 
infection. Local culinary practices which fail to kill encysted metacercariae 
(salting, pickling, smoking, or eating raw food) may result in human infection. 
Metacercariae excyst in the duodenum of the definitive host, migrate through the 
ampulla of Vater and ascend the biliary tree to small and medium-sized biliary 
ducts, where they mature into adult flukes over 30-45 days and sexually 
reproduce. C. sinensis adult flukes grow to between 10 and 25mm and can 
produce approximately 4000 eggs per fluke per day. Adult O. viverrini and O. 
felineus flukes grow to between 8 and 12mm and can shed approximately 200 
eggs per fluke per day(5). 
 
The lifecycle of the Fasciolids, Fasciola hepatica and Fasciola gigantica, is similar 
to Clonorchis and Opisthorchis, with the distinction that neither requires a 
vertebrate second intermediate host. The definite hosts of both species are 
domestic livestock, predominantly sheep and cattle. F. hepatica is also known to 
infect goats, buffalo, horses, donkeys, mules, camels, hogs, rats, deer and rabbits 
as definite hosts. Eggs are released into the biliary ducts and then faeces of the 
host and become embryonated in water where they hatch, releasing free-
swimming miracidia. Miracidia penetrate the freshwater snails intermediate 
host and, like Clonorchis and Opisthorchis, develop into sporocysts then rediae, 
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reproduce asexually, and are subsequently released as cercariae from the snail 
(5). Fasciola cercariae encyst (as metacercariae) on aquatic vegetation such as the 
watercress, water lotus, water caltrop, water chestnut, or water lily(7) and 
infection of the definitive or incidental (human) host is acquired from eating 
contaminated plants. Dandelion leaves, lettuce, spearmint, algae, corncob, alfalfa, 
spinach, broccoli, morning glory have also been described as vectors in human 
infection(5, 7). Metecercariae are also found on water surfaces, and use of 
contaminated water for drinking, or washing food or kitchen utensils may result 
in human infection(7). Outbreaks have also been seen in chewers of Khat, a 
narcotic leaf which may become contaminated by water used to keep it fresh 
during transport(8). 
 
Once ingested, Fasciola metacercariae excyst in the duodenum. In contrast to the 
Opisthorchidae, which ascend the biliary tree, Fasciola larvae bore directly 
through the intestinal wall, peritoneal cavity and liver parenchyma, reaching the 
large biliary ducts where they mature into adults. Aberrant migration is well 
described with ectopic fascioliasis recorded in many tissue types. Adult F. 
hepatica flukes can grow up to 2.9cm and produce up to 25,000 eggs per fluke 
per day(5). F. gigantica, as the name suggests, are much larger (growing up to 
5.2cm) and can produce 8000-10,000 eggs per fluke per day(5). 
 
 
AFFECTED POPULATIONS 
 
Human trematodiases are geographically limited to areas where the necessary 
intermediate hosts coexist and local culinary habits fail to kill metacercariae. In 
general, warm and wet rural areas with poor sanitation have the highest 
prevalence of liver fluke infection. Human migration and environmental, 
behavioural and agricultural changes mean that the geographical distribution of 
the individual species is in flux. Liver fluke infection may be diagnosed in those 
with a travel history to endemic areas. Primary infection may also occur in areas 
where these trematodes do not live if metacercariae in fish or vegetable products 
are imported(8). There are also reports of liver fluke transmission via infected 
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liver transplants(9). 
  
Diagnostic difficulty and species misidentification mean that there may be 
considerable unrecognized overlap in epidemiology of individual species, with 
co-endemicity potentially under reported. 
 
Clonorchis sinensis infection is endemic in China, Korea, Taiwan, Northern 
Vietnam, and far eastern Russia(10). Local prevalence is as high as 85% in some 
regions of China(11). Worldwide, an estimated 601 million people are at risk, with 
an estimated 35 million infected, 15 million of whom are in China(12-14). C. sinensis 
was previously described in Japan, but with improved sanitation and disease 
control there have been no reported locally transmitted cases since 1991(11). The 
incidence of clonorchiasis in China is rising, potentially due to an increase in 
commercial freshwater fish farming(12).  
 
Opisthorchis viverrini is endemic in Thailand, Laos, Cambodia and central and 
south Vietnam. An estimated 10 million people are infected worldwide, 80% of 
whom reside in Thailand(7). A study in Thailand showed O. viverrini infection 
rates ranging between 2 and 71% in different districts(15). 
 
Opisthorchis felineus is found in the former USSR including Belarus and Ukraine 
and has been found in animals in Germany, Italy, Poland, Portugal, and Spain 
over the last 50 years(5, 16). Locally transmitted human infection has been 
reported in Germany and Italy, with a recent outbreak reported from the region 
around Lake Bolsena(17). An estimated 1.2 million people are affected worldwide, 
predominantly in Russia(5). 
 
Fasciola hepatica is a far more widespread parasite than the Chinese and oriental 
liver flukes. It has a worldwide distribution and is a common zoonosis 
throughout Eurasia and parts of South America and Africa(5). Previous estimates 
suggest between 2·4 and 17.0 million people are infected worldwide(7). Cattle 
and sheep herders are at higher risk and, in endemic areas, infection is more 
common in children(5). Prevalence in the Northern Bolivian Altiplano approaches 
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100%(18) and notably high prevalence has also been reported in the Mantaro 
valleys (34·2%) and Puno region (15·64%) of Peru, Corozal in Puerta Rico 
(10·9%), and the inner Porto area of Portugal (3·2%)(19). The wide range of F. 
hepatica may be related to the ability of the metacercariae to encyst on aquatic 
plants and water surfaces without the requirement and associated selective 
constraint of a specific second intermediate host.  
  
Fasciola gigantica is known to be endemic in Africa and Asia. As these areas 
harbour both F. hepatica and F. gigantica, and the ova of which cannot be reliably 
distinguished on stool microscopy, the exact distributions of each species remain 
unclear. The distribution of F. gigantica is currently understood to extend from 
the Nile Delta in Egypt through Africa and Asia as far as Japan. The distribution of 
F. gigantica is limited by the distribution of its intermediate host, the radix group 
of Freshwater snail(20). Reports of human infection were rare before 1989, when 
an outbreak of fascioliasis caused by F. gigantica was reported in Iran(21). 
Recently, an outbreak was reported in China(22), where infection had not 
previously been documented. 
 
It should be noted that the estimates of prevalence of the human liver flukes are 
in most cases decades old and likely inaccurate. Likewise knowing their true 
distribution is limited by the sparsity of up to date information, the high 
incidence of asymptomatic human infection, and the nature of the liver flukes as 
zoonoses. 
 
CLINICAL MANIFESTATIONS 
 
CLONORCHIASIS AND OPSITHORCHIASIS 
Acute and chronic infection with Clonorchis sinensis or Opisthorchis 
viverrini/felineus is usually asymptomatic, with symptoms only reported in 5-
10% of cases(23). Studies in Korea and Thailand demonstrate that intensity of 
infection, inferred by stool egg counts, is positively associated with incidence of 
symptoms(24). Acute symptoms of clonorchiasis and opisthorchiasis include 
malaise, weakness, anorexia, flatulence, nausea, vomiting, abdominal pain and 
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diarrhoea. Obstructive jaundice may occur in heavy infections(23). Hepatomegaly, 
often more pronounced in the left hepatic lobe(25), is common and can be greater 
than 7cm below the costal margin in heavy infections. Splenomegaly is a rare 
finding(23). Acute symptoms seem to occur more frequently in O. felineus 
infections than in C. sinensis and O. viverrini, and fever is sometimes seen (7). 
Acute symptoms usually resolve within a few weeks (7). 
 
Clonorchis and Opisthorchis infections are long lasting. C. sinensis parasites have 
been reported to survive for up to 26 years and O. viverrini up to 10 years in 
humans(26). Chronic infections are often benign but various complications can 
occur late in the clinical course. Chronic symptoms may mirror acute symptoms, 
and may be due to chronic irritation of bile ducts or physical obstruction by liver 
flukes. Cholangitis, cholecystitis, obstructive jaundice, periportal fibrosis, 
cholelithiasis, and cholangiocarcinoma are all recognised consequences of 
clonorchiasis and opisthorchiasis(27). Pancreatitis, as a result of pancreatic duct 
obstruction, has been described but is rare and usually mild(5). Recurrent 
pyogenic cholangitis (RPC) is the single most common complication(28). 
 
Cholangiocarcinoma 
The most important complication of chronic liver fluke infection is 
cholangiocarcinoma , a rare cancer with a high mortality which is in part due to 
the absence of early symptoms and consequent late diagnosis (29). Clonorchis 
sinensis and Opisthorchis viverrini are both listed as Class 1 (carcinogenic to 
humans) biological carcinogens by the International Agency for Research on 
Cancer (IARC)(6). 
 
The association between cholangiocarcinoma and liver fluke infection was first 
demonstrated from studies of Opisthorchis viverrini infection in Thailand. 
Thailand has a high incidence of cholangiocarcinoma, and regions within 
Thailand with the highest prevalence of O. viverrini infection also have the 
highest incidence of cholangiocarcinoma(30). In the Khon Kaen region of North-
east Thailand, where O. viverrini prevalence has historically approached 100%, 
the age-standardised incidence rates (ASR) of cholangiocarcinoma was 
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113·4/100,000 population/year in men (compared to 0·3-1·5/100,000 
population/year worldwide)(30).  
 
The association between Clonorchis sinensis infection and cholangiocarcinoma 
has been shown in Korean studies. Korea also shows the same pattern of higher 
incidence of cholangiocarcinoma in districts with the highest prevalence of C. 
sinensis infection(31).  
 
There is a paucity of studies on a potential link between Opisthorchis felineus and 
cholangiocarcinoma. There are some epidemiological data from Russia 
suggesting a higher incidence of cholangiocarcinoma in areas endemic for O. 
felineus(16) and a high prevalence of O. felineus infection in autopsy studies of 
patients with primary liver malignancies (fluke infection seen in 42 of 44 liver 
malignancy patients in one study)(32). Additionally there are some animal data 
suggesting cholangiocarcinoma as a sequalae of O. felineus infection(33). Lower 
prevalence and a lower intensity of research into O. felineus compared to the 
other Far Eastern liver flukes may explain the difficulty in proving a link between 
O. felineus infection and cholangiocarcinoma, although it does seem likely that 
such a link exists. 
 
The mechanism of carcinogenesis is incompletely understood and is the subject 
of ongoing research(34, 35). Much of the data relate to Opisthorchis viverrini 
induced cholangiocarcinoma. As Clonorchis or Opisthorchis feed on biliary 
epithelium, mechanical damage, as well as release of fluke excretory-secretory 
products, lead to inflammation and ulceration of biliary epithelium, resulting in 
epithelial metaplasia and eventually periductal fibrosis and dysplasia(36). 
 
Chronic periportal inflammation caused by Opisthorchis viverrini, results in liver 
cell necrosis and deposition of fibrotic tissue, with periportal fibrosis similar to 
that seen in primary sclerosing cholangitis (a strong risk factor for 
cholangiocarcinoma(37)). Fibrosis replaces the periportal inflammation over 
time(38). Re-infection, which is common and often continual in endemic areas, 
results in more severe inflammation, and accelerated fibrosis(39). Induction of 
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fibrosis after inflammation is an important part of the pathway of pathological 
changes that lead to cholangiocarcinoma(40). These abnormalities do not occur in 
all patients, with a subset producing a stronger inflammatory response and then 
faster and more advanced periportal fibrosis deposition, predisposing them to 
cholangiocarcinoma(36). Genetic or environmental factors, such as alcohol, 
smoking, and levels of fruit and vegetable intake, are likely involved here(41). The 
presence of the fermented foods present in a North-Eastern Thai diet may 
enhance the development of fibrosis in O. viverrini infected individuals(42). 
Melatonin, known to protect against liver injury in multiple cancer types, has 
been shown to reduce tumour burden, and increase survival in hamsters with O. 
viverrini-related cholangiocarcinoma(43). 
 
Excretory-secretory products of liver flukes likely have additional effects 
promoting tumourigenesis. Secreted carcinogenic oxysterols, which can induce 
production of other carcinogens, have been found in liver tissue of Opisthorchis 
viverrini infected hamsters, and human cholangiocarcinoma tissue(37, 44).  
A granulin-like growth factor secreted by O. viverrini has been shown to promote 
tumour cell growth(45). Excretory-secretory products of Clonorchis sinensis may 
induce hyperplasia and metaplasia of biliary cells with subsequent 
transformation to cholangiocarcinoma(46), and have been shown to suppress 
apoptosis of cholangiocarcinoma(47), and hepatocellular carcinoma(48) cells in 
vitro. C. sinensis excretory-secretory products may also induce cancer-related 
microRNA expression(49). Excretory-secretory products of O. viverrini induce 
expression of Interleukin-6 (IL-6)(50). Extracellular vesicles containing excretory-
secretory products, are taken up by cholangiocytes, and induce release of IL-6, as 
well as changes in protein expression associated with cancer(51). IL-6 drives 
release of human pro-granulin, which is associated with development of many 
cancers, including cholangiocarcinoma(52), and may represent a biomarker for 
development of advanced periportal fibrosis and cholangiocarcinoma(36, 50). 
Other cytokines, especially Interferon-γ (IFN-γ), Interleukin-10 (IL-10), and 
Lymphotoxin-α (LT-α) are significantly raised in O. viverrini related 
cholangiocarcinoma, and may indicate dysregulation of the immune response(53). 
Similar cytokine overexpression and dysregulation is seen in C. sinensis 
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infection(34). 
 
Upregulation of inducible nitric oxide synthase (iNOS) and subsequent 
oxidative/nitritative DNA damage has been demonstrated in Opisthorchis 
viverrini-related cholangiocarcinoma in humans(54), and in Clonorchis sinensis 
infected mice(49, 55). Oxidative/nitritative damage to proteins via reactive oxygen 
species may prolong the oxidative stress(37). iNOS is a target for nuclear factor κB 
(NFκB), and other targets of NFκB have been shown to be upregulated in O. 
viverrini infection(56). NFκB-mediated inflammation is also seen in C. sinensis 
infection(46, 55). Likewise inhibition of NFκB with cepharanthine has been shown 
to have anti-tumour activity against cholangiocarcinoma in mice(57), and may 
represent a potential future treatment. Use of ciclosporin to suppress the raised 
levels of cyclophilin A seen in O. viverrini has been shown reduce 
cholangiocarcinoma cell proliferation and tumour growth in a mouse model(43). 
Long-term (three months) curcumin treatment has been shown to reduce 
periductal fibrosis in O. viverrini infected hamsters(58). 
 
Opisthorchis viverrini induced cholangiocarcinomas have been found to have 
different gene expression profiles to non-liver fluke related cholangiocarcinoma, 
with high expression of UGT2B11, UGT1A10, CHST4, SULT1C1 genes related to 
xenobiotic metabolism, whereas non-liver fluke related cholangiocarcinomas 
have upregulation of genes related to growth factor signalling(59). The lesser K-
ras gene mutation, is seen in 56% of O. viverrini-related cholangiocarcinoma 
(versus 0.0-16.7% of cholangiocarcinoma from other causes), and p16 DNA 
methylation is seen in 100% of O. viverrini-related cholangiocarcinoma (versus 
28.3% of cholangiocarcinoma from other causes)(59-62). Additionally novel 
cholangiocarcinoma-related genes such as BAP1, ARID1A, MLL3, IDH1/2, RNF43, 
PEG3, GNAS, and ROBO2 have been identified in O. viverrini-related 
cholangiocarcinoma(63). NFκB, a pivotal regulator of gene expression, is known to 
be specifically involved in the expression of genes of the UGT2B family(64). There 
are a number of other molecular targets that may be useful in recognition or 
treatment of liver-fluke cholangiocarcinoma in the future(56). 
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There has been a great deal of research into the involvement of Helicobacter spp. 
in the development of cholangiocarcinoma in Opisthorchis viverrini infection. 
Helicobacter pylori can be found in 90% of O. viverrini infected hamsters (versus 
43.3% of non-O. viverrini infected hamsters), and Helicobacter bilis can be found 
in 40% of O. viverrini infected hamsters (versus 26.7% of non-O. viverrini 
infected hamsters). Prevalence of H. pylori and H. bilis was lower in O. viverrini 
infected hamsters treated with praziquantel and antibiotics, rather than 
antibiotics alone, indicating O. viverrini is a potential reservoir for H. pylori and H. 
bilis(65). O. viverrini infection may also cause changes in bile acid composition that 
reduce alkalinity which may allow for easier colonisation of H. pylori (66, 67), and 
may even directly contribute to biliary inflammation(68). Chronic cholestasis may 
also contribute to a low pH environment favourable to H. pylori(69). H. bilis causes 
similar pre-malignant pathological changes to those seen in liver fluke infection 
in the biliary tree in an animal model (chronic hepatitis, hepatic dysplasia, 
fibrosis, and biliary hyperplasia)(70). Cell inflammation and proliferation of 
biliary and gallbladder epithelial cells has been shown to be significantly higher 
in O. viverrini-related cholangiocarcinoma with H. pylori DNA detected in bile 
samples, compared to those without detectable biliary H. pylori infection(71). The 
increased inflammatory and proliferative process in these patients was more 
pronounced in biliary infections with H. pylori harbouring the cagA gene(71), an 
important virulence factor known to induce the severe inflammation associated 
with gastric adenocarcinoma(72). H. bilis and H. pylori infection is associated with 
cholangiocarcinoma in patients in both areas endemic for human liver fluke 
infection and in areas where human liver fluke infection is rarely seen(73-75). 
 
There is no difference in treatment for Opisthorchis viverrini-related 
cholangiocarcinoma compared to non O. viverrini-related cholangiocarcinoma, 
and prevention through improved public health measures, education, and mass 
O. viverrini treatment may help reduce the burden of disease. There are a 
number of molecular targets for potential future therapies, and further research 
into the role of anti-Helicobacter antibiotics, melatonin, ciclosporin and curcumin 
his needed.  
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In 2009, the IARC found no evidence of an association between liver fluke 
infection and hepatocellular carcinoma(6), however a recent meta-analysis of 
seven studies did demonstrate a positive association(27). Severin, an 
excretory/secretory product of Clonorchis sinensis inhibits apoptosis of HCC cell 
lines in vitro(48). Co-infection with C. sinensis in chronic hepatitis B infection, has 
been shown to be associated with higher hepatitis B virus (HBV) DNA titres(76). 
More research is needed in this area. 
 
 
FASCIOLIASIS 
Infections with Fasciola hepatica and F. gigantica are clinically indistinguishable 
and can be split into acute, latent (when parasites mature into adults), and 
chronic phases. Acute symptoms are caused by the tissue destruction and acute 
inflammation associated with larval migration through intestine, peritoneum 
and liver parenchyma, as well as a generalised allergic reactions to parasite 
antigens(5). Fever and abdominal pain (which may be excruciating), are the most 
frequently reported symptoms(5, 77). Anorexia, flatulence, nausea, diarrhoea, 
urticaria and cough are also common. Hepatomegaly, splenomegaly, jaundice, 
and ascites may be seen. Acute symptoms may last 2-4 months, but in endemic 
areas re-infection may cause episodic symptoms and overlapping of acute and 
chronic symptoms(5). 
 
Human fascioliasis is a chronic disease, with adult flukes living up to 13·5 
years.(78) The flukes cause inflammation and hyperplasia of biliary epithelium, 
portal triad and duct dilatation, periductal fibrosis, necrotising arterial vasculitis 
and portal venous thrombosis(5). The large size of the flukes mean that 
obstruction of the large biliary ducts occurs commonly. Cholangitis (which may 
be recurrent), cholecystitis, cholelithiasis, liver abscesses, subcapsular 
haemorrhages, cirrhosis, and pancreatitis are known complications of human 
fascioliasis(5). There is no known association between Fasciola infection and 
cholangiocarcinoma. 
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DIAGNOSIS OF LIVER FLUKE INFECTIONS 
 
HAEMATOLOGICAL AND BIOCHEMICAL ABNORMALITIES  
 
Eosinophilia is often the most apparent haematological abnormality in 
clonorchiasis and opisthorchiasis however, even in heavy infections, eosinophilia 
may not always be present (5, 24).  
 
Eosinophilia is reported in up to 100% of cases of fascioliasis in the acute phase, 
and is often associated with hypergammaglobulinaemia(5). Anaemia is common 
in fascioliasis and is related to chronic blood loss from damaged biliary 
epithelium(5). Alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), alkaline phosphatase (ALP), γ-glutamyl transferase (GGT) and bilirubin 
are often raised during larval migration (79), and during the chronic phase. 
 
PARASITOLOGICAL DIAGNOSIS 
 
Parasitological diagnosis can be obtained by microscopic identification of eggs in 
faeces, duodenal aspirates, bile specimens or surgical samples. Identification of 
eggs in stool by microscopy is the most common method of diagnosis. Wet 
mount preparations are widely used, but may miss light infections(80). 
Concentration techniques using formalin-ether or centrifugation are therefore 
used in hospital laboratories to detect light infections(81). However, difficulty in 
using egg morphology to differentiate species of liver fluke, and even confusion 
with intestinal flukes or non-pathogenic trematodes, reduces the specificity and 
sensitivity of this method(81, 82). Therefore eggs of light, or early infections may 
not be detected(24, 83). Eggs do not appear in stool until 3-4 months post ingestion 
in fascioliasis, and 3-4 weeks in clonorchiasis and opisthorchiasis(5, 82), when the 
flukes have finished migration and reached maturity. If flukes cause obstruction 
of the biliary tree, eggs may not be passed to stool, and so endoscopic or 
percutaneous biliary aspirates may be more useful for diagnosis(5). Adult flukes 
may be seen in stool examination after expulsion from the biliary tree post-
treatment. The sensitivity of microscopic diagnosis may be increased by 
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repeating samples(84), but there is a need for improved point-of-care diagnostic 
methods both for the eggs, as a proxy to adult worm burden and measure of 
environmental contamination, as well as for direct detection of the adult worms 
or adult worm antigens. 
 
IMMUNODIAGNOSIS AND MOLECULAR DIAGNOSTICS 
Crude adult somatic extracts for enzyme-linked immunosorbent assay (ELISA) , 
Excretory/secretory (ES) antigens, and several other antigens from Clonorchis 
sinensis and Opisthorchis viverrini have been used with higher sensitivity than 
stool egg microscopic detection, and may therefore be of use assessing treatment 
success(85). Stool antigen tests for Clonorchis and Opisthorchis have also been 
developed, and may be of use in detection of light infections(85). Stool PCR assays 
of O. viverrini DNA have also been developed with 100% sensitivity and 98% 
specificity in heavy infections, and although less sensitive for light infections 
(68%)(86), may enable detection of light or early infection when stool microscopy 
is negative(85). Access to serological, antigen and PCR diagnostics for Clonorchis 
and Opisthorchis varies, and validation of these tests for widespread use is still 
required.  
 
Immunological tests for Fasciola hepatica are better validated than those for 
Clonorchis and Opisthorchis, and allow confirmation of early acute disease 2-4 
weeks after infection(82). The CDC currently recommend enzyme immunoassays 
(EIA) with excretory-secretory (ES) antigens combined with confirmation of 
positives by immunoblot.  
 
IMAGING 
Ultrasound may be of use in diagnosis of liver fluke infections. The findings of 
hepatomegaly, gallstones, sludge, intrahepatic duct stones, poorly-functioning 
gall bladder, increased portal vein diameter, intrahepatic bile duct dilatation, 
increased splenic thickness, or high hepatic pulsation index are non-specific but 
supportive(87, 88). The most specific finding for clonorchiasis and opisthorchiasis 
are visualisation of aggregates of flukes as floating echogenic foci(89) and 
periductal fibrosis. Degree of periductal fibrosis measured by echogenicity is 
 15 
associated with burden of disease.(88). Computed Tomography (CT) provides 
similar information, and is more sensitive in detecting dilated and thickened 
small bile ducts associated with recurrent cholangitis(90). Magnetic Resonance 
Imaging (MRI) may reveal flukes as filling defects in the biliary system(91) and 
may identify bile duct dilatation, enhancement, and thickening. Magnetic 
Resonance Cholangiopancreatography (MRCP) is the most sensitive modality for 
the detection of cholangiocarcinoma(92). 
 
In acute fascioliasis, multiple, small (2-3cm) liver lesions, representing migratory 
tracks, have been reported to be present in up to 90% of confirmed fascioliasis 
cases presenting to a hospital in Turkey(93). These are usually hypoechoic on US, 
but may be hyper or anechoic. If not visible on US they may still be seen on CT 
scans. Larger lesions are often necrotic. Perihepatic or subcapsular collections 
may be seen in acute fascioliasis(93). The migration tracks of Fasciola in the 
parenchymal phase, may be visible as subcapsular enhancing hypo- or 
hyperintense lines on T1W and T2W images on MRI(94).  
 
Adult Fasciola flukes may also be visualised directly as mobile structures in the 
common bile duct on US or CT during the latent or chronic phase(93). Enlarged 
porta hepatis nodes are visible in 51% on US or CT(93). Biliary abnormalities are 
present in 45% of cases and may include visible parasites in the gallbladder or 
bile ducts, or biliary duct dilatation, thickening, oedema or abnormal 
enhancement(93, 95). After eight weeks ductal ectasia may be seen with bile duct 
thickening, dilatation and tortuosity occurring after 12 weeks(95). Other findings 
include mild splenomegaly, ectopic inflammation in the abdominal wall or 
bowel(93).  
 
ENDOSCOPIC DIAGNOSIS 
Endoscopic Retrograde Cholangiopancreatography (ERCP) is an effective 
diagnostic tool with endoscopic aspiration of bile demonstrating Clonorchis 
sinensis ova in 100% and live worms in 50% of patients in a study of 18 patients 
presenting to a hospital in Taiwan(96). Bile duct aspiration may allow for 
parasitological diagnosis even when stool sample are negative(97). Clonorchis 
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flukes may also be visualised directly as filamentous or elliptical filling defects, 
which are pathognomonic clonorchiasis on ERCP(96). This finding has been 
reported as occurring in 83% of patients at ERCP, but may be obscured by 
contrast medium(96). It has been suggested that careful observation of contrast 
medium and use of diluted contrast may increase sensitivity(96). Other findings 
include small, irregular filling defects, diffuse tapering of intrahepatic ducts with 
intra- and extra-hepatic bile duct dilatation and hazy appearance of the 
intrahepatic ducts, solitary or multiple intrahepatic cystic dilatations producing a 
mulberry-like appearance, and biliary duct ectasia(96). 
 
ERCP is considered the gold standard for bile duct imaging in fascioliasis. Typical 
findings include dilated large bile ducts, with a jagged appearance distally, 
containing small linear filling defects and cresenteric shadows representing 
adult Fasciola flukes which can be retrieved endoscopically(98). Fascioliasis may 
also be diagnosed by direct visualisation of fluke as a floating linear filling 
structure, or spiral shaped mobile membrane, with common bile duct dilatation 
on endoscopic ultrasound(99). 
 
SURGICAL DIAGNOSIS 
Laparoscopy commonly demonstrates hepatomegaly and multiple raised 
vermilliform nodules on the surface of the liver and peritoneum in fascioliasis 
(100). Adult liver flukes of all species are large enough to be visible 
macroscopically, and so may be seen during cholecystectomy, or explorative 
laparotomy(5).  
 
HISTOLOGICAL DIAGNOSIS 
In clonorchiasis and opisthorchiasis common histological findings include biliary 
epithelial adenomatous proliferation, and goblet cell metaplasia, with periductal 
fibrosis and bile duct thickening in long standing infection(5). Fluke eggs may 
embed in damaged epithelium and cause granulomatous inflammation with 
eosinophilic, mononuclear and neutrophilic infiltration(5). Necrotising arterial 
vasculitis and portal venous thrombosis have been described(5). Mucinous and 
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squamous metaplasia of the pancreatic duct is seen in pancreatitis caused by 
fluke infection(5). 
 
In fascioliasis, histology of liver lesions most commonly show central necrosis, 
cellular debris with Charcot-Leyden crystals surrounded by an eosinophilic and 
inflammatory cell infiltrate and multiple calcific foci. Eggs or adult flukes are 
occasionally seen on liver biopsy(101). Egg granulomas and eosinophilic infiltrate 
may be seen in all liver fluke infections(102). 
 
MANAGEMENT 
 
MEDICAL MANAGEMENT 
For Clonorchis sinensis, Opisthorchis viverrini and Opisthorchis felineus infection, 
WHO recommends praziquantel treatment with either 25mg of drug/kg body 
weight (mg/kg) 3 times daily for 2-3 consecutive days, or a single dose of 
40mg/kg. The Centers for Disease Control and Prevention (CDC) recommend a 
higher dose of 75mg/kg/day for 2 days for treatment of Opisthorchis infections, 
with this dose shown to be safe, and effective(103). Recommendations for use are 
extended to pregnant and lactating women although it remains a category B drug 
as formal randomised trials are lacking. WHO also recommend use in children, 
although data are lacking in the under 4 years of age group. Praziquantel 
treatment yields cure rates of 85-100% in Clonorchis infections(104, 105), and 
100% cure rates with praziquantel have been reported in O. viverrini and O. 
felineus infections with 25mg/kg/day over 3 days(106),. Cure rates of 90-95% are 
reported with the 40mg/kg single dose in Opisthorchis infections(107), although 
cure rates are much lower (22.7-33.3%) in Clonorchis infections(104). 
The CDC recommends albendazole 10mg/kg/day for 7 days as second line 
treatment, this is a category C drug in pregnancy, but is approved for use in the 
second and third trimester. Albendazole should be used with caution in lactating 
women, and effects in children under 6 years of age are thought to be minimal, 
but are not fully investigated. Albendazole has however been used in WHO 
supported prevention programmes in children as young as 1 year(108). 7 days of 
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albendazole is effective in treating Clonorchis in animal models, with cure rates 
of 90-92·6% at 6 months (109). Cure rates are only 63% after 7 days of 
albendazole in human Opisthorchiasis(110). 89-94% cure rates have been 
reported after 20-30 days of mebendazole in human opisthorchiasis(111), and 
may represent an alternative to albendazole.GH 
 
Resistance to praziquantel has not been described in Clonorchis or Opisthorchis. 
There is a single report of failure of praziquantel treatment in Vietnam, with cure 
rates of only 29% in 21 patients, although this may have been due to inadequate 
dosing rather than drug resistance(112). A new drug, tribendimidine, appears as 
effective as praziquantel for clonorchiasis with fewer side-effects(113). A recent 
phase two clinical trial demonstrated cure rates up to 91·5% in adults, and up to 
98·5% in children in O. viverrini infections treated with 400mg and 100mg of 
tribendimidine, respectively(114).  
  
Fascioliasis is the only trematode infection which does not respond to 
praziquantel, and triclabendazole is the only drug recommended for this 
infection by WHO(115). Triclabendazole can be used in both acute and chronic 
fascioliasis as it is active against both immature and adult flukes. It is given as a 
single dose of 10mg/kg(116). Double-dose therapy (10mg/kg dose given, and 
repeated at 12-24 hours) is recommended in heavy infections, or if there is no 
response to single-dose therapy(116). Cure rates of 92·2-100% are described in 
adults with a two-dose regimen(117, 118), with 79·2% cure rates described with the 
single-dose regimen(119). Cure rates of 95% using the 10mg/kg dose have 
recently been described in children, with 100% cure rates using two doses of 
7.5mg/kg(120). Reports of resistance to triclabendazole in livestock are 
increasingly common, and more recently likely resistance in human fascioliasis 
has been detected in the Netherlands and Peru(121, 122). Evidence from animal 
studies suggests triclabendazole resistance may be overcome by co-
administration with the enzyme inhibitor ketonazole(123). The artemisinins 
artesunate, artethemer, and OZ78 are active against triclabendazole-resistant 
Fasciola hepatica(124), and combination therapy may provide a solution to 
triclabendazole-resistant flukes, although further work is required(125). 
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Nitazoxanide 500mg/day twice daily, for 7 days can be used as an alternative 
therapy for fascioliasis and has been shown to be efficacious in treating human 
Fasciola gigantica infections with cure rates of 78%(126). Nitazoxanide is 
considered second line treatment for human fascioliasis by the CDC(116). Cure 
rates of 60% in adults and 40% of children with F. hepatica infection have been 
reported(127). A study of Mexican children with F. hepatica infection, produced 
cure rates of 94% with nitazoxanide 7.5mg/kg twice daily, for 7 days, rising to 
100% with a second treatment course (128).  
WHO recommend mass treatment with praziquantel 40mg/kg at 12 or 24 month 
intervals in populations endemic for clonorchiasis or opisthorchiasis, and mass 
treatment with triclabendazole 10mg/kg as a single dose of school age children, 
or the entire community, in sub-districts, villages or communities where cases of 
fascioliasis appear to be clustered(129). 
ENDOSCOPIC MANAGEMENT 
ERCP has a well-described role in the treatment of biliary obstruction, and may 
be of use in any liver fluke infection causing biliary obstruction cholangitis, or 
cholecystitis from flukes or secondary stones or bacterial infection(130-132). 
Sphincterotomy and direct retrieval of flukes may be of value in diagnosis and 
treatment, but needs to be supported by medical therapy. There are cases 
reports of successful endoscopic management of fascioliasis in refractory cases 
using ERCP and flushing of the biliary system with povidone iodine(133). Further 
work is needed to establish the validity of this treatment. 
 
RARE LIVER FLUKES 
Infection with Dicrocoelium dendriticum, which may be acquired through the 
ingestion of infected ants, has been reported sporadically and can manifest in a 
similar way to clonorchiasis and opisthorchiasis(134). Successful treatment with 
praziquantel and triclabendazole have been reported(135). Metorchis conjunctus 
has been described as causing asymptomatic carriage in Sioux populations of 
Ontario, Canada(136). An outbreak of 19 patients related to consumption of white 
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sucker, prepared as sashimi has been reported (137). Metorchis bilis is an 
important cause of human liver fluke infection in the Ob river basin of western 
Siberia, and has a similar presentation to Opisthorchis felineus(138). Metorchis 
orientalis eggs have been found in the stool of 4·2% of the human population of 
Ping Yuan County of Guangdong Province, China and, although not identified in 
the biliary system of humans directly, has been identified in the biliary systems 
of local ducks, cats and dogs(139). Human infection with Amphimerua noverca, 
Opisthorchis guayaquilensis, Pseudamphistomum truncatum, Dicrocoelium hospes, 
and Eurytretna pancreaticum have been described but are limited to a handful of 
case reports(5). 
 
CONCLUSION 
Liver fluke infection is rare in developed countries and, with the exception of 
Fasciola hepatica, is usually limited to travellers from endemic areas. More work 
is needed on the epidemiology of individual species, which can be difficult to 
distinguish from one another. Diagnosis to the level of genus is usually made by 
examination of stool for ova, although this lacks both sensitivity and specificity. 
The association of some of these parasites with cholangiocarcinoma makes 
identification and treatment of liver fluke infections important. Treatment with 
praziquantel for clonorchiasis and opisthorchiais, or triclabendazole for 
fascioliasis is highly effective, and mass treatment in endemic areas is advised. 
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